Last checked at 15 Mar 2022 10:58
Hikma Pharmaceuticals PLC - EIP C Vesting
LONDON, 15 March 2022: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 12 March 2019 under the 2014 Executive Incentive Plan ("EIP") Element C.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Said Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 38,862 |
d) | Aggregated information - Volume - Price
- Total |
38,862 £0.00 £0.00 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Siggi Olafsson
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Sigurdur Olafsson |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 16,299 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 26,377
Price(s): £19.88 Volume(s): 16,299 |
d) | Aggregated information - Volume - Price
- Total |
42,676 £19.88 £324,024.12 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Siggi Olafsson
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Sigurdur Olafsson |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | The Company granted the named individual above a conditional award to acquire Shares under a bespoke arrangement in respect of the first year of service only that operates on the same basis as Element C of the 2014 Executive Incentive Plan (EIP). 27,498 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 44,502
Price(s): £19.88 Volume(s): 27,498 |
d) | Aggregated information - Volume - Price
- Total |
72,000 £19.88 £546,660.24 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Mazen Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Vice Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 26,514 |
d) | Aggregated information - Volume - Price
Total |
26,514 £0.00 £0.00 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Riad Mishlawi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 23,030 |
d) | Aggregated information - Volume - Price
- Total |
23,030 £0.00 £0.00 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Majda Labadi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Majda Labadi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 12,064 |
d) | Aggregated information - Volume - Price
- Total |
12,064 £0.00 £0.00 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Bassam Kanaan |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 19,195 |
d) | Aggregated information - Volume - Price
- Total |
19,195 £0.00 £0.00 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Khalid Nabilsi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 17,710 |
d) | Aggregated information - Volume - Price
- Total |
17,710 £0.00 £0.00 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Brian Hoffmann
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Brian Hoffmann |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 4,310 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 6,975
Price(s): £19.88 Volume(s): 4,310 |
d) | Aggregated information - Volume - Price
- Total |
11,285 £19.88 £85,682.80 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Susan Ringdal |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 4,820 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 5,383
Price(s): £19.88 Volume(s): 4,820 |
d) | Aggregated information - Volume - Price
- Total |
10,203 £19.88 £95,821.60 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Henriette Nielsen
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Henriette Nielsen |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 2,670 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 4,320
Price(s): £19.88 Volume(s): 2,670 |
d) | Aggregated information - Volume - Price
- Total |
6,990 £19.88 £53,079.60 |
e) | Date of the transaction | 14 March 2022 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760
15 March 2022